These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 9213009

  • 1. Alendronate prevents cyclosporin A-induced osteopenia in the rat.
    Sass DA, Bowman AR, Yuan Z, Ma Y, Jee WS, Epstein S.
    Bone; 1997 Jul; 21(1):65-70. PubMed ID: 9213009
    [Abstract] [Full Text] [Related]

  • 2. Combined flurbiprofen and cyclosporin-A does not attenuate bone loss and exaggerates renal impairment.
    Sass DA, Rucinski B, Bryer HP, Mann GN, Yuan Z, Ma Y, Jee WS, Epstein S.
    Bone; 1996 Oct; 19(4):381-6. PubMed ID: 8894144
    [Abstract] [Full Text] [Related]

  • 3. Short-term systemic insulin-like growth factor-1 is unable to prevent cyclosporin A-induced osteopenia in the rat.
    Mann GN, Sass DA, Chen HK, Buchinsky FJ, Bryer HP, Ma YF, Jee WS, Rucinski B, Epstein S.
    Calcif Tissue Int; 1996 Jul; 59(1):38-44. PubMed ID: 8661983
    [Abstract] [Full Text] [Related]

  • 4. The endothelin receptor antagonist, L-754,142 does not prevent cyclosporine A-induced osteopenia in rats.
    Sodam BR, Awumey EM, Sampson WH, Epstein S.
    Calcif Tissue Int; 2001 Feb; 68(2):117-21. PubMed ID: 11310347
    [Abstract] [Full Text] [Related]

  • 5. Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat.
    Bryer HP, Isserow JA, Armstrong EC, Mann GN, Rucinski B, Buchinsky FJ, Romero DF, Epstein S.
    J Bone Miner Res; 1995 Jan; 10(1):132-8. PubMed ID: 7747620
    [Abstract] [Full Text] [Related]

  • 6. Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia.
    Mann GN, Jacobs TW, Buchinsky FJ, Armstrong EC, Li M, Ke HZ, Ma YF, Jee WS, Epstein S.
    Endocrinology; 1994 Sep; 135(3):1077-83. PubMed ID: 8070349
    [Abstract] [Full Text] [Related]

  • 7. Effect of cyclosporin A on bone mineral metabolism in experimental diabetes mellitus in the rat.
    Epstein S, Takizawa M, Stein B, Katz IA, Joffe II, Romero DF, Liang XG, Li M, Ke HZ, Jee WS.
    J Bone Miner Res; 1994 Apr; 9(4):557-66. PubMed ID: 8030444
    [Abstract] [Full Text] [Related]

  • 8. The role of testosterone in cyclosporine-induced osteopenia.
    Bowman AR, Sass DA, Dissanayake IR, Ma YF, Liang H, Yuan Z, Jee WS, Epstein S.
    J Bone Miner Res; 1997 Apr; 12(4):607-15. PubMed ID: 9101372
    [Abstract] [Full Text] [Related]

  • 9. Rapamycin: a bone sparing immunosuppressant?
    Romero DF, Buchinsky FJ, Rucinski B, Cvetkovic M, Bryer HP, Liang XG, Ma YF, Jee WS, Epstein S.
    J Bone Miner Res; 1995 May; 10(5):760-8. PubMed ID: 7543725
    [Abstract] [Full Text] [Related]

  • 10. Influence of age on cyclosporin A-induced alterations in bone mineral metabolism in the rat in vivo.
    Katz I, Li M, Joffe I, Stein B, Jacobs T, Liang XG, Ke HZ, Jee W, Epstein S.
    J Bone Miner Res; 1994 Jan; 9(1):59-67. PubMed ID: 8154310
    [Abstract] [Full Text] [Related]

  • 11. Prostaglandin E2 alleviates cyclosporin A-induced bone loss in the rat.
    Katz IA, Jee WS, Joffe II, Stein B, Takizawa M, Jacobs TW, Setterberg R, Lin BY, Tang LY, Ke HZ.
    J Bone Miner Res; 1992 Oct; 7(10):1191-200. PubMed ID: 1456087
    [Abstract] [Full Text] [Related]

  • 12. 17 beta-estradiol prevents osteopenia in the oophorectomized rat treated with cyclosporin-A.
    Joffe I, Katz I, Jacobs T, Stein B, Takizawa M, Liu C, Berlin J, Epstein S.
    Endocrinology; 1992 Mar; 130(3):1578-86. PubMed ID: 1537307
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The bisphosphonate 2-PEBP inhibits cyclosporin A induced high-turnover osteopenia in the rat.
    Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S.
    J Lab Clin Med; 1990 Jan; 115(1):62-8. PubMed ID: 2299257
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in rats.
    Joffe I, Katz I, Sehgal S, Bex F, Kharode Y, Tamasi J, Epstein S.
    Calcif Tissue Int; 1993 Jul; 53(1):45-52. PubMed ID: 8348384
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Transforming growth factor-beta administration modifies cyclosporine A-induced bone loss.
    Goodman GR, Dissanayake IR, Bowman AR, Pun S, Ma Y, Jee WS, Bryer HP, Epstein S.
    Bone; 2001 Jun; 28(6):583-8. PubMed ID: 11425645
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo.
    Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WS, Epstein S.
    Transplantation; 1994 Apr 27; 57(8):1231-7. PubMed ID: 7513912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.